Despite being common and clinically burdensome, subjective tinnitus is diagnosed and characterised primarily through subjective reporting. Objective biomarkers could transform tinnitus care by enabling reproducible identification, stratification, and monitoring, but their clinical utility for detecting tinnitus and quantifying its severity remains unclear....
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change yet — no biomarker has sufficient clinical validation to replace or meaningfully supplement subjective tinnitus assessment in routine practice; findings are preliminary and require replication.
Identifying reliable objective biomarkers for tinnitus could transform diagnosis, patient stratification, and treatment-outcome measurement, addressing a longstanding gap in tinnitus clinical research.
- 01Systematic review published in Hearing Research targeting objective biomarkers of subjective tinnitus.
- 02Aims to move tinnitus characterization beyond purely self-reported scales and questionnaires.
- 03Covers both tinnitus presence (does the patient have it?) and clinical burden (how severely does it affect them?).
- 04No single validated biomarker currently exists for routine clinical use.
- 05Findings may inform future clinical trial design and patient selection frameworks.
Objective biomarkers can be identified that correlate with subjective tinnitus presence and clinical burden.
studypartially supported- PMID
- 42612615
- DOI
- 10.1016/j.heares.2026.109770.
- Journal
- Hearing Research
- Publication type
- systematic_review
- Evidence level
- 1a
- Population
- Patients with subjective tinnitus across studies included in the review
- Intervention
- Objective biomarker measurement (e.g., neuroimaging, electrophysiology, blood/biochemical markers) for tinnitus
Primary outcomes
Biomarker sensitivity/specificity for tinnitus presence; Biomarker correlation with clinical burden of tinnitus